Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2018, Article ID 8727941, 13 pages
https://doi.org/10.1155/2018/8727941
Research Article

Comprehensive Validation of Snapback Primer-Based Melting Curve Analysis to Detect Nucleotide Variation in the Codon 12 and 13 of KRAS Gene

1Department of Clinical Laboratory, Huashan Hospital, Fudan University, 200040, China
2Baoshan Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai, 201999, China
3Central Laboratory, Huashan Hospital, Fudan University, Shanghai 200040, China
4Department of Clinical Laboratory, Huashan Hospital North, Fudan University, Shanghai, 201907, China

Correspondence should be addressed to Ming Guan; moc.oohay@88gnimnaug and Zhiyuan Wu; moc.liamtoh@111nauyihzuw

Received 10 November 2017; Accepted 13 August 2018; Published 10 October 2018

Academic Editor: Salvatore Gallone

Copyright © 2018 Qunfeng Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. V. T. H. B. M. Smit, A. J. M. Boot, A. M. M. Smits, G. J. Fleuren, C. J. Cornelisse, and J. L. Bos, “KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas,” Nucleic Acids Research, vol. 16, no. 16, pp. 7773–7782, 1988. View at Publisher · View at Google Scholar · View at Scopus
  2. C. P. Vaughn, S. D. Zobell, L. V. Furtado, C. L. Baker, and W. S. Samowitz, “Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer,” Genes, Chromosomes and Cancer, vol. 50, no. 5, pp. 307–312, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Dearden, J. Stevens, Y.-L. Wu, and D. Blowers, “Mutation incidence and coincidence in non small-cell lung cancer: Meta-analyses by ethnicity and histology (mutMap),” Annals of Oncology, vol. 24, no. 9, pp. 2371–2376, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. I. M. Ahearn, K. Haigis, D. Bar-Sagi, and M. R. Philips, “Regulating the regulator: Post-translational modification of RAS,” Nature Reviews Molecular Cell Biology, vol. 13, no. 1, pp. 39–51, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. I. A. Prior, P. D. Lewis, and C. Mattos, “A comprehensive survey of ras mutations in cancer,” Cancer Research, vol. 72, no. 10, pp. 2457–2467, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. Y. Pylayeva-Gupta, E. Grabocka, and D. Bar-Sagi, “RAS oncogenes: weaving a tumorigenic web,” Nature Reviews Cancer, vol. 11, no. 11, pp. 761–774, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. A. G. Stephen, D. Esposito, R. G. Bagni, and F. McCormick, “Dragging ras back in the ring,” Cancer Cell, vol. 25, no. 3, pp. 272–281, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. R. G. Amado, M. Wolf, M. Peeters et al., “Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer,” Journal of Clinical Oncology, vol. 26, no. 10, pp. 1626–1634, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Lièvre, J. B. Bachet, D. le Corre et al., “KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer,” Cancer Research, vol. 66, no. 8, pp. 3992–3995, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. M. J. Sorich, M. D. Wiese, A. Rowland, G. Kichenadasse, R. A. McKinnon, and C. S. Karapetis, “Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials,” Annals of Oncology, vol. 26, no. 1, pp. 13–21, 2015. View at Publisher · View at Google Scholar · View at Scopus
  11. C. S. Karapetis, S. Khambata-Ford, D. J. Jonker et al., “K-ras mutations and benefit from cetuximab in advanced colorectal cancer,” The New England Journal of Medicine, vol. 359, no. 17, pp. 1757–1765, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. J. Y. Douillard, K. S. Oliner, and S. Siena, “Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer,” The New England Journal of Medicine, vol. 369, no. 11, pp. 1023–1034, 2013. View at Publisher · View at Google Scholar
  13. C. Bokemeyer, I. Bondarenko, A. Makhson et al., “Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer,” Journal of Clinical Oncology, vol. 27, no. 5, pp. 663–671, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. G. J. Riely and M. Ladanyi, “KRAS mutations: An old oncogene becomes a new predictive biomarker,” Journal of Molecular Diagnostics, vol. 10, no. 6, pp. 493–495, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. G. J. Riely, J. Marks, and W. Pao, “KRAS mutations in non-small cell lung cancer,” Proceedings of the American Thoracic Society, vol. 6, no. 2, pp. 201–205, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. A. C. Tsiatis, A. Norris-Kirby, R. G. Rich et al., “Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications,” Journal of Molecular Diagnostics, vol. 12, no. 4, pp. 425–432, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. A. H. Lang, H. Drexel, S. Geller-Rhomberg et al., “Optimized allele-specific real-time PCR assays for the detection of common mutations in KRAS and BRAF,” Journal of Molecular Diagnostics, vol. 13, no. 1, pp. 23–28, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. J. T. Ney, S. Froehner, A. Roesler, R. Buettner, and S. Merkelbach-Bruse, “High-resolution melting analysis as a sensitive prescreening diagnostic tool to detect KRAS, BRAF, PIK3CA, and AKT1 mutations in formalin-fixed, paraffin-embedded tissues,” Archives of Pathology & Laboratory Medicine, vol. 136, no. 9, pp. 983–992, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. K. Brotto, E. Malisic, M. Cavic, A. Krivokuca, and R. Jankovic, “The usability of allele-specific PCR and reverse-hybridization assays for KRAS genotyping in serbian colorectal cancer patients,” Digestive Diseases and Sciences, vol. 58, no. 4, pp. 998–1003, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. O. Nordgård, S. Oltedal, E. A. M. Janssen et al., “Comparison of a PNA clamp PCR and an ARMS/Scorpion PCR assay for the detection of K-ras mutations,” Diagnostic Molecular Pathology, vol. 21, no. 1, pp. 9–13, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. Z. Zuo, S. S. Chen, P. K. Chandra et al., “Application of COLD-PCR for improved detection of KRAS mutations in clinical samples,” Modern Pathology, vol. 22, no. 8, pp. 1023–1031, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. S. Ogino, T. Kawasaki, M. Brahmandam et al., “Sensitive sequencing method for KRAS mutation detection by pyrosequencing,” Journal of Molecular Diagnostics, vol. 7, no. 3, pp. 413–421, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. C. M. McCourt, D. G. McArt, K. Mills et al., “Validation of Next Generation Sequencing Technologies in Comparison to Current Diagnostic Gold Standards for BRAF, EGFR and KRAS Mutational Analysis,” PLoS ONE, vol. 8, no. 7, p. e69604, 2013. View at Google Scholar · View at Scopus
  24. V. Taly, D. Pekin, L. Benhaim et al., “Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients,” Clinical Chemistry, vol. 59, no. 12, pp. 1722–1731, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. N. Waddell, M. Pajic, and A.-M. Patch, “Whole genomes redefine the mutational landscape of pancreatic cancer,” Nature, vol. 518, no. 7540, pp. 495–501, 2015. View at Publisher · View at Google Scholar
  26. Cancer Genome Atlas Research Network, “Integrated genomic characterization of pancreatic ductal adenocarcinoma,” Cancer cell, vol. 32, no. 2, pp. 185–203, 2017. View at Google Scholar
  27. K. E. Pierce and L. J. Wangh, “Linear-after-the-exponential polymerase chain reaction and allied technologies: Real-time detection strategies for rapid, reliable diagnosis from single cells,” Single Cell Diagnostics: Methods and Protocols, pp. 65–85, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. J. N. Weinstein, E. A. Collisson, G. B. Mills, K. R. M. Shaw, B. A. Ozenberger, K. Ellrott et al., “The cancer genome atlas pan-cancer analysis project,” Nature Genetics, vol. 45, no. 10, pp. 1113–1120, 2013. View at Publisher · View at Google Scholar
  29. L. B. Alexandrov, S. Nik-Zainal, D. C. Wedge, P. J. Campbell, and M. R. Stratton, “Deciphering Signatures of Mutational Processes Operative in Human Cancer,” Cell Reports, vol. 3, no. 1, pp. 246–259, 2013. View at Publisher · View at Google Scholar
  30. K. Litchfield, B. Summersgill, S. Yost et al., “Whole-exome sequencing reveals the mutational spectrum of testicular germ cell tumours,” Nature Communications, vol. 6, 2015. View at Google Scholar · View at Scopus
  31. Y.-C. Tang, B. R. Williams, J. J. Siegel, and A. Amon, “Identification of aneuploidy-selective antiproliferation compounds,” Cell, vol. 144, no. 4, pp. 499–512, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. W. Pan, Y. Yang, H. Zhu, Y. Zhang, R. Zhou, and X. Sun, “KRAS mutation is a weak, but valid predictor for poor prognosis and treatment outcomes in NSCLC: A meta-analysis of 41 studies,” Oncotarget , vol. 7, no. 7, pp. 8373–8388, 2016. View at Publisher · View at Google Scholar · View at Scopus
  33. T. Yokota, “Are KRAS/BRAF mutations potent prognostic and/or predictive biomarkers in colorectal cancers?” Anti-Cancer Agents in Medicinal Chemistry, vol. 12, no. 2, pp. 163–171, 2012. View at Publisher · View at Google Scholar · View at Scopus
  34. Y. Shen, X. Han, J. Wang et al., “Prognostic impact of mutation profiling in patients with stage II and III colon cancer,” Scientific Reports, vol. 6, p. 24310, 2016. View at Publisher · View at Google Scholar
  35. A. Orue, M. Rieber, and H. Wang, “Optimized Multiplex Detection of 7 KRAS Mutations by Taqman Allele-Specific qPCR,” PLoS ONE, vol. 11, no. 9, p. e0163070, 2016. View at Publisher · View at Google Scholar
  36. L. S. Kristensen, T. E. Kjeldsen, H. Hager, and L. L. Hansen, “Competitive amplification of differentially melting amplicons (CADMA) improves KRAS hotspot mutation testing in colorectal cancer,” BMC Cancer, vol. 12, no. 1, p. 548, 2012. View at Google Scholar · View at Scopus